Jun 5, 2022
Lytix Biopharma with new data at ASCO - featured in Finansavisen and in Dagens Medisin

Lytix announced data from its ATLAS-IT-04 trial in patients with metastatic soft tissue sarcoma (STS) as a poster at the American Society of Clinical Oncology (ASCO) 2022, June 5th. Data from this Phase II proof of concept study shows that LTX-315 in combination with ACT was able to stabilize the disease in 3 out of 4 fully treated patients in this hard-to-treat patient population, and that the LTX-315 treatment generated tumor-specific T cells.

In connection with the presentation of the new data, Lytix was interviewed and featured in Dagens Medisin and Finansavisen.


Read the article in Dagens Medisin

Read the article in Finansavisen